Pfizer has secured a $5.2billion acquisition of Anacor Pharmaceuticals which will enable the pharmaceutical giant to sell an eczema treatment that could reach up to $2billion in sales. The deal is expected to close by mid-2017. The deal is expected to be finalised in the third quarter and is not set to affect Pfizer's 2016 fiscal guidance.
Pfizer has secured a $5.2billion acquisition of Anacor Pharmaceuticals which will enable the pharmaceutical giant to sell an eczema treatment that could reach up to $2billion in sales. Crisaborole, the anti-inflammatory tropical treatment created by Anacor, could serve over 30 million Americans as a first-line option after receiving approval from the FDA. The deal is expected to be finalised in the third quarter and is not set to affect Pfizer's 2016 fiscal guidance.